Measuring Excipient-Market Growth - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Measuring Excipient-Market Growth
Moderate growth is projected for the global excipients market. Excipient producers target blends and new grades for improving functionality and performance.


Pharmaceutical Technology


Fast-melt or quick-dissolving formulations pose certain challenges in excipient selection. "APIs that have an extreme sensitivity to water may pose problems for API stability since the excipients usually contain water in the amount of 4–5% by weight," says Widmaier. "In this case, it can help to coat the API to protect it from the water present in the excipient."

The pressure on the API during tableting is another consideration. "The excipient should diminish the pressure on the coated API granules, so that these granules are not being damaged during compression to the final tablet," says Widmaier.

The filler and binder may also affect the ODT. The filler should dissolve readily in water and saliva without increasing the solution's viscosity. "Otherwise, the entrance of water into the tablet will be delayed, and the disintegration time increases," explains Widmaier. "For the binder, quick dissolution diminishes the speed of disintegration."

Beneo–Palatinit (Mannheim, Germany) markets a high-solubility grade of "galenIQ 721" (pharmaceutical-grade isomalt) for ODTs. Beneo–Palatinit introduced galenIQ two years ago as a filler and binder. The product is derived from sucrose. Through enzymatic transglucosidation, sucrose is converted to the disaccharide 6-O-α-D-glucopyranosyl fructose, a reducing compound, which is hydrogenated. This process results in the stereoisomer disaccharide alcohol 1-O-α-D-glucopyranosyl-D-mannitol dihydrate and 6-O-α-D-glucopyranosyl-D-sorbitol in an approximate equimolecular mixture, explains Bodo Fritzsching, head of pharmaceutical sales and technical services at Beneo–Palatinit. Through additional processing, the ratio of the two molecular components can be varied, resulting in grades with different solubilities. The lower soluble galenIQ 720 (solubility 24.5 g/100 g at 20 C) is used in sublinguals that dissolve slowly in the oral cavity or for swallowable tablets that erode within several minutes. The other grade, galenIQ 721 (solubility 41.5 g/100 g at 20 C), shows good disintegration properties and can be used with crospovidone for fast and very fast disintegrating tablets.

Isomalt is used with ODTs formulated through direct compression. "The number of fillers and binders in this area is limited because these bulk excipients have to fulfill special requirements from a technology and sensorial view," says Fritzsching. Because galenIQ is based on sucrose, it offers taste-masking potential, thus adding functionality to the formulation.

Other producers point to limitations in attaining multifunctionality. "The concept of an excipient product that provides two functions, such as binder and disintegration, is appealing," says Bee. "However, there are usually compromises in the overall performance and a loss in formulation flexibility. The excipient is not as effective at doing one of the functions as effectively as an excipient that provides a single function." ISP provides "Polyplasdone" (crospovidone) for ODTs.

Controlled-release formulations. Excipient producers are also targeting excipients to improve the performance of controlled-release formulations. "Direct compression is the lowest cost, quickest-to scaleup process for controlled-release formulations," says Kacee Ender, pharmaceutical applications development specialist in the pharmaceutical excipient research and development group of Dow Wolff Celullosics, a business unit of the Dow Chemical Company (Midland, MI). Dow Wolff Celullosics recently introduced two new hypromellose products for direct compression of controlled-release matrix oral dosage forms. "Methocel" K4M and "Methocel" K100M premium DC grades are viscosity grades designed to improve powder flowability while maintaining compressibility, tablet hardness, and controlled-release performance, says Ender.

JRS Pharma's "ProSolv SMCC" (silicified microcrystalline cellulose (MCC) is a multifunctional exicipient that can be used in controlled-release applications. "The surface roughness and colloidal silicon dioxide (CSD) adds flow, but it allows the excipient to be more effective in producing dry-blended, ordered mixtures, which in turn improves content uniformity," explains Guy. "The product is differentiable from MCC–CSD blends in its interaction with water. Several companies have used this property for matrix-controlled release systems."

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ, 08830, tel. 732.346.3072,

References

1. "Excipients in Pharmaceuticals" Report No. PHM010E, BCC Research (Norwalk, CT, 2006).

For more on innovation in excipients, see the online exclusive: "Tracking the Potential of Excipients"


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here